artenimol has been researched along with Carcinoma, Hepatocellular in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 8 (53.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, C; Li, Z; Shao, J; Su, Y; Sun, S; Xia, S; Xu, X; Zhang, B; Zhang, F; Zhang, Y; Zhang, Z; Zhao, D; Zheng, S | 1 |
| Guo, Y; Hao, L; Ji, J; Li, C; Liu, Y; Peng, Q; Shi, X; Xue, Y; Zhang, Z; Zheng, K | 1 |
| Gao, Y; Guo, Y; Hao, L; Ji, J; Li, C; Liu, Y; Peng, Q; Shi, X; Xue, Y; Zhang, Z | 1 |
| Che, CM; Hu, D; Liu, Y; Lok, CN; Mao, X; Ruan, ML; Yam, JWP; Zhang, C | 1 |
| Deng, YN; Guh, JH; Hsu, LC; Hsu, YF; Huang, TE; Kung, FL; Marchesi, E; Marchetti, P; Navacchia, ML; Perrone, D | 1 |
| Gao, Y; Gong, Y; Liang, H; Lu, J; Peng, Q; Shi, X; Yang, J; Yang, Y; Yue, Y; Zhang, Y | 1 |
| Guo, D; Guo, J; Hou, C; Liu, T; Wang, T; Yu, X; Zhang, S | 1 |
| Chen, J; He, J; Lin, L; Liu, Y; Su, Y; Wei, H; Yang, Y; Zhou, C | 1 |
| Guo, D; Hou, C; Liu, T; Wang, S; Yu, X | 1 |
| Feng, BM; Han, XL; Li, YT; Sun, YC; Tang, L; Yuan, LX | 1 |
| Cui, Q; Li, J; Li, S; Ren, L; Shi, X; Wang, L | 1 |
| Chai, L; Chen, T; Liu, H; Qin, G; Quan, Y; Wang, X; Wu, S; Zhang, L; Zhao, C | 1 |
| Hou, J; Wang, D; Wang, H; Zhang, R | 1 |
| Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V | 1 |
| Chen, GG; Lai, PB; Yun, J; Zhang, CZ; Zhang, H | 1 |
15 other study(ies) available for artenimol and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Dihydroartemisinin Induces Ferroptosis in HCC by Promoting the Formation of PEBP1/15-LO.
Topics: Animals; Antimalarials; Apoptosis; Arachidonate 15-Lipoxygenase; Artemisinins; Carcinoma, Hepatocellular; Cell Proliferation; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylethanolamine Binding Protein; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma.
Topics: Animals; Artemisinins; B7-H1 Antigen; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Lipid Droplets; Liver Neoplasms; Mice; Mice, Knockout; Perilipin-2; YAP-Signaling Proteins | 2022 |
Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma.
Topics: Animals; Artemisinins; Bile Acids and Salts; Carcinoma, Hepatocellular; Cholesterol 7-alpha-Hydroxylase; Humans; Liver; Liver Neoplasms; Mice; YAP-Signaling Proteins | 2022 |
Dihydroartemisinin engages liver fatty acid binding protein and suppresses metastatic hepatocellular carcinoma growth.
Topics: Artemisinins; Carcinoma, Hepatocellular; Fatty Acid-Binding Proteins; Humans; Liver; Liver Neoplasms | 2023 |
Anticancer Activity and Molecular Mechanisms of an Ursodeoxycholic Acid Methyl Ester-Dihydroartemisinin Hybrid via a Triazole Linkage in Hepatocellular Carcinoma Cells.
Topics: Apoptosis; Artemether; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Tandem Mass Spectrometry; Ursodeoxycholic Acid | 2023 |
Dihydroartemisinin inhibited interleukin-18 expression by decreasing YAP1 in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Interleukin-18; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Transcription Factors | 2023 |
Network pharmacology-based analysis of mechanisms of the anti-hepatocellular carcinoma effect by dihydroartemisinin.
Topics: Antineoplastic Agents; Artemisinins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Glycosylation; Humans; Lectins; Liver Neoplasms; N-Acetylglucosaminyltransferases; Nucleophosmin; Signal Transduction | 2019 |
Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53 | 2019 |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
Topics: Antimalarials; Antineoplastic Agents; Artemisinins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Sorafenib; Up-Regulation | 2020 |
[Preliminary study of dihydroartemisin in inhibiting invasion and metastasis of hepatoma cells].
Topics: Artemisinins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; ErbB Receptors; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction | 2020 |
Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells.
Topics: Amino Acid Chloromethyl Ketones; Antimalarials; Artemisinins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Caspase 1; Caspases; DNA-Binding Proteins; Hep G2 Cells; Humans; Inflammasomes; Liver Neoplasms; Mitochondria; Reactive Oxygen Species; TOR Serine-Threonine Kinases | 2019 |
Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Artemisinins; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Membrane Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction | 2015 |
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.
Topics: Animals; Antineoplastic Agents; Artemether; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Neoplasms; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines.
Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholangiocarcinoma; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Humans; Liver Neoplasms; Receptors, Transferrin; Transferrin | 2011 |
Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Artemisinins; bcl-2 Homologous Antagonist-Killer Protein; Carcinoma, Hepatocellular; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cytochromes c; Drug Screening Assays, Antitumor; Genes, p53; Humans; Liver Neoplasms; Mice; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2012 |